The minimally important difference of the Asthma Control Test

Schätz, Michael; Kosinski, Mark; Yarlas, Aaron; Hanlon, Jennifer; Watson, Melanie; Jhingran, Priti

doi:10.1016/j.jaci.2009.06.053

Cited by 458 publications

(365 citation statements)

References 18 publications

Supporting

Mentioning

339

Contrasting

Unclassified

Order By: Relevance

“…Each item includes responses with values from 1 to 5 to give a final ACT score of 5 (poorly controlled asthma) to 25 (wellcontrolled asthma). An improvement of ≥ 3 units in the ACT score is considered to be the minimal important difference [17,19].…”

Section: Introductionmentioning

confidence: 99%

Real-world effectiveness and safety of omalizumab in patients with uncontrolled severe allergic asthma from the Czech Republic

Kirchnerová¹,

Valena²,

Novosad³

et al. 2019

pdia

View full text Add to dashboard Cite

A b s t r a c tIntroduction: This was a sub-group analysis of patients with uncontrolled persistent allergic asthma (AA) in the healthcare setting of the Czech Republic, from a global non-interventional, 2-year post-marketing, observational eXpeRience registry. Aim: To evaluate the real-life effectiveness and safety of omalizumab. Material and methods: Patients with uncontrolled persistent AA (currently defined by the Global Initiative for Asthma (GINA) as uncontrolled severe AA) who started omalizumab treatment 15 weeks before inclusion in the registry were analysed for physicians' global evaluation of treatment effectiveness (GETE), asthma symptoms, corticosteroid use, exacerbation rate, asthma control, quality of life, healthcare utilisation and safety during a 24-month observation period. Results: One hundred and fourteen patients from the Czech Republic were enrolled in the eXpeRience registry. A total of 88.9% of the patients were evaluated as responders to omalizumab according to the GETE assessment at week 16. From baseline to month 24: mean change in forced expiratory volume in 1 s (FEV 1 ) was 137 ml and the daily dose of OCS decreased (11.6 mg to 6.4 mg prednisolone equivalent); the percentage of patients with no severe clinically significant exacerbations increased (29.5% to 95.1%); Asthma Control Test scores improved (12.4 to 17.3) and mean total number of days of asthma-related medical healthcare use decreased (6.8 days to 0.4 days). Conclusions: The results of this subgroup analysis support the evidence that add-on omalizumab therapy is effective and well tolerated for management of patients with uncontrolled persistent AA in the Czech Republic. Global evaluation of treatment effectiveness assessment is a reliable predictor of long-term response to omalizumab treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Real-world effectiveness and safety of omalizumab in patients with uncontrolled severe allergic asthma from the Czech Republic

Kirchnerová¹,

Valena²,

Novosad³

et al. 2019

pdia

View full text Add to dashboard Cite

show abstract

“…10,11 Additionally, it is not uncommon for abstracts that are published as part of conference proceedings to have inconsistencies compared with the final study publication or to describe studies that are never published as full articles. [12][13][14][15][16] When a study with an English-language abstract but published in a foreign language was identified, the abstract was assessed against the full set of inclusion/exclusion criteria. If the study appeared to fit the inclusion criteria, we evaluated whether excluding the study might result in language bias (e.g., if the findings differ from other included studies.)…”

Section: Publication Criteriamentioning

confidence: 99%

Effectiveness and Safety of Bronchial Thermoplasty in Management of Asthma

D’Anci¹,

Lynch²,

Leas³

et al. 2017

View full text Add to dashboard Cite

“…The minimum clinically important difference for a tool is the smallest change in score that can be considered clinically important. 35 The minimum clinically important difference enhances the ability of clinicians and researchers to evaluate the effectiveness of interventions. For the ACT, a difference of 3 points has been shown to be a significant minimum clinically important difference.…”

Section: Responsivenessmentioning

confidence: 99%

“…For the ACT, a difference of 3 points has been shown to be a significant minimum clinically important difference. 35 …”

Section: Responsivenessmentioning

confidence: 99%

Asthma Control Assessment Tools

Alzahrani

Becker

2015

Respir Care

View full text Add to dashboard Cite

, and they emphasize periodic assessment of asthma control once treatment is established. Accurate assessment of asthma control is difficult due to the complexity of asthma control and due to the limitations in the traditional methods of assessment, such as lung function tests, physician assessment, and patients' self-assessment. Relying solely on the role of lung function tests is insufficient to reflect the status of asthma control, since patients with asthma may have normal spirometry between exacerbations. Clinicians often overestimate the level of asthma control. Similarly, it is not uncommon for patients to overestimate how well their asthma is controlled, and, therefore, they under-report asthma symptoms and fail to recognize the impact that asthma has on their daily life. As a result, several tools have been developed to quantify the level of asthma control, identify patients at risk, and evaluate the effect of asthma management. This review examines the commonly 106RESPIRATORY CARE • JANUARY 2016 VOL 61 NO 1 used asthma control assessment tools in terms of content, psychometric properties, methods of administration, limitations, and ability to reflect the overall status of asthma control, which can aid clinicians in selecting the most appropriate tool for their needs.

show abstract

The minimally important difference of the Asthma Control Test

Cited by 458 publications

References 18 publications

Real-world effectiveness and safety of omalizumab in patients with uncontrolled severe allergic asthma from the Czech Republic

Real-world effectiveness and safety of omalizumab in patients with uncontrolled severe allergic asthma from the Czech Republic

Effectiveness and Safety of Bronchial Thermoplasty in Management of Asthma

Asthma Control Assessment Tools

Contact Info

Product

Resources

About